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OBJECTIVES: Imatinib is considered standard of care for 1st line treatment of
chronic myeloid leukemia (CML) in Brazil. Long-term treatment effectiveness,
however, is jeopardized by questionable adherence among patients receiving
imatinib. The goal of this study is to document the adherence of CML patients to
imatinib and the impact of these adherence levels on long-term prognosis.
METHODS: A longitudinal cohort analysis was performed using SIA/DATASUS
data from January 2008 through Jun 2010. Inclusion criteria included patients 
18 years old; diagnosed with CML (ICD10 92.1) in Chronic Phase; beginning 1st
line treatment with imatinib from January 1, 2008 to December 31, 2008; and a
minimum follow-up period of 6 months. Adherence of all patients that met
inclusion criteria was calculated based on medication possession ratio (MPR)
over a 15-month period. Patients were categorized as adherent (MPR  0.9) or
non-adherent (MPR  0.9). Using uni and multivariate logistic regression we
analyzed the following covariates: adherence, age, gender, region of country
and other comorbidities for their influence on progression rates. RESULTS: In
total, 386 patients, 56% males and mean (SD) age 48 (15) years, were included in
the study. There were 210 (54%) patients calculated as being adherent (MPR 
0.9). At the end of the 24-months of follow-up, 20% patients from the non-
adherent group had progressed, versus 10% in the adherent group (log-rank
p0,02). Patients from North, South and Southeast regions of Brazil had signif-
icantly higher adherence as compared with those from Northeast or Center-
west. According to the multivariate logistic regression, lower adherence is sig-
nificantly associated with higher progression rates. CONCLUSIONS: Adherence
to imatinib is associated with a better progression-free survival profile, with
statistical significance being observed after a 24-months period. Non-adherence
was observed in 46% of the population studied.
PCN80
PATIENT PREFERENCES FOR TOXICITIES ASSOCIATED WITH CHEMOTHERAPIES
FOR ADVANCED BREAST CANCER
Beusterien K1, Grinspan J1, Tencer T2, Brufsky A3, Visovsky C4
1Oxford Outcomes Ltd., Bethesda, MD, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA, 3University of
Pittsburgh Cancer Institute, Pittsburgh, PA, USA, 4University of Nebraska Medical Center,
Omaha, NE, USA
OBJECTIVES: Given that treatments for advanced breast cancer are palliative
rather than curative, the patient-perceived impact of chemotherapy is a critical
outcome. To date, no studies have estimated the strength of patient preferences for
a comprehensive set of toxicities associated with breast cancer treatments. The
objective of this study was to measure patient preferences for treatment-related
toxicities in advanced breast cancer. METHODS: This was a cross-sectional Web-
based survey of women with stage I through IV breast cancer who were recruited
through web forums and newspaper ads. Using the standard gamble approach,
each participant valued her own current health state in the absence of side effects
and nine health states describing that current health state plus each of nine grade
III/IV toxicities. Toxicity disutilities were calculated by subtracting the utility for
current health from that for current health plus the toxicity. RESULTS: Of the 103
patients who completed the web survey, 21 had to be excluded given irrational
responses. The mean ‘current health’ utility for the sample was 0.837. Patients
assigned higher utilities to their current health state than to the toxicity states.
Alopecia received the highest utility (mean0.79; disutility  4.6) of all the side
effects, and diarrhea received the lowest (mean0.69; disutility  14.7). Patterns
were similar across disease stages, although patients with more advanced disease
(stage III or IV) generally assigned lower utilities (greater disutilities) to the various
toxicities. For several side effects (alopecia, nausea, vomiting, fatigue, mucositis,
and diarrhea), patients who had experience with the side effect reported higher
utility values compared to those who had not experienced the side effect.
CONCLUSIONS: To our knowledge, this study was the first to report strength of
preferences for toxicities associated with advanced breast cancer treatments. The
utilities obtained in this studymay be used in future cost-effectiveness evaluations
of breast cancer therapies.
PCN81
DIVERSITY IN BELIEFS ABOUT THE CAUSES OF CANCER: A QUALITATIVE
APPROACH TO EVALUATE CANCER PATIENTS’ UNDERSTANDING TOWARDS
CANCER AND ITS CAUSES
Farooqui M1, Hassali MA2, Knight A2, Shafie AA2, Tan BS3, Farooqui MA4
1Universiti Teknologi MARA, Penang, Malaysia, 2Universiti Sains Malaysia (USM), Penang,
Malaysia, 3Penang General Hospital, Penang, Malaysia, 4Allianze College of Medical Sciences,
Penang, Malaysia
OBJECTIVES: Peoples’ beliefs towards health and illness play an important role in
health seeking behavior. Cancer patients’ beliefs regarding cancer have been re-
ported to be important factors affecting screening and treatment seeking behavior.
This study was aimed to evaluate cancer patients’ beliefs about cancer and its
causes. METHODS: A qualitative research approach was adapted. After obtaining
institutional ethical approval, patients with different types and stages of cancer
from the three major ethnic groups in Malaysia were purposively selected to par-
ticipate in the interview. Twenty patients whom had consented were interviewed
using a semi-structured interview guide. After conducting 18 interviews the satu-
ration point was reached and nomore themes were emerged from the subsequent
interviews. All interviews were audiotaped, transcribed verbatim and translated
into English for thematic content analysis. RESULTS: The emergent themes were
as follows: unknown reasons, internal factors, environmental perceptions, and
spiritual attributions. In this preliminary investigation cancer patients described
cancer as a disease present in every human being and itmay become visible during
the course of life. Genetic predisposition, female gender and hematological factors
were reported to be some of the internal factors. Unhealthy life style habits such as
smoking, high consumption of red meat, and pesticides in foods were some of the
environmental factors that were described. Among those who claimed to have
healthy habits prior to the illness, there was a rejection of the notion that un-
healthy life style was a cause. A strong spiritual connection was found as many
patients described their cancer diagnosis as ‘God’s will.’ CONCLUSIONS: This ex-
ploratory investigation suggests that cancer patients’ understanding about cancer
is complex in nature. The findings may help health care providers remove myths
about cancer and reassure patients during the treatment decisionmaking process.
It may also help in improving patients’ compliance towards the proven cancer
therapies.
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OBJECTIVES: To assess patients’ knowledge of chronic myeloid leukemia (CML)
treatment response categorizations and to evaluate health-related quality-of-life
(HRQOL) outcomes and treatment satisfaction among CML patients achieving dif-
ferent levels of responses. METHODS: CML patients were invited to complete an
on-line survey that assessed their knowledge of different CML treatment-response
categorizations. Data on HRQOL outcomes and treatment satisfaction were also
collected. Chi-square and Fisher’s test were used for statistical comparisons.
RESULTS: 123 patients obtained through the ACOR database completed the survey.
The mean age of respondents was 63 years, 48.8% were male, and 95.9% had some
level of college experience. Over 90% were familiar with the different levels of CML
treatment responses, with 96.8% self-reporting a current hematologic response,
70.7% a current cytogenetic response, and 68.3% a molecular response. However,
71.5% felt CML patients needmore information on the types of responses, with the
desire for information to come from their physicians (66.7%) rather than fromother
staff (28.5%) or pamphlets (23.6%). Achieving a molecular response (as opposed to
hematologic/cytogenetic responses) generated the greatest satisfaction with their
physician (78.6%), medication (86.6%), outlook on life (85.7%), and day-to-day func-
tioning (85.7%). The percentage of patients rating their own health as excellent/
very good was 43.1% among those with a molecular response and 41.7% with a
cytogenetic response. However, 21.9% of all subjects rated their health as fair/poor.
CONCLUSIONS: Achievement of a molecular response was associated with a
higher satisfaction with a patient’s physician, medication, and outlook on life, as
well as an overall improvement in self-reported health ratings. Even in this highly
educated ACOR population, a need for physician-directed information about vari-
ous response criteria and counseling about the value of obtaining a molecular
response is desired.
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OBJECTIVES: To evaluate and compare the preferences for targeted therapy for
metastatic renal cell carcinoma in cancer patients, patients’ family members and
medical experts. METHODS: Using discrete choice experiment, survey questions
were constructed on the basis of six attributes of efficacy, adverse events and
administration. We designed two kinds of scenario sets as first-line therapy and
therapy for poor prognosis. A total of 485 individuals were completed question-
naire: 140 cancer patients, 60 patients’ familymembers and 285medical experts(39
oncology doctors, 34 oncology nurses, 133 nurses and 79 pharmacists).RESULTS: In
first-line therapy and therapy for poor prognosis, all six attributes in studies were
statistically significant so they were important for choices. In first-line therapy
coefficients of six attributes in patients and medical experts were all statistically
significant but not progression free survival(PFS) in patients’ family members. Be-
tween patients and doctors, PFS, hand-foot skin reaction(HFSR) and administration
were statistically significantly different. Between patients and nurses, the coeffi-
cients of bonemarrow suppression, HFSR, gastrointestinal perforation and admin-
istration were significantly different. In therapy for poor prognosis, six attributes
were statistically significant in patients but not administration in patients’ family
members, not HFSR, interstitial pneumonitis in doctors. Between patients and
doctors, coefficients of PFS, HFSR, asthenia and interstitial pneumonitis were dif-
ferent significantly. Between patients and nurses, five attributes were significantly
different except HFSR.CONCLUSIONS: Efficacy, adverse events and administration
were all important for preference in respondents. Comparisons of coefficients be-
tween subgroups represented different preferences of those groups. Medical ex-
perts especially doctors showed quite different preferences from patients and pa-
tients’ family members. Doctors considered efficacy more important than adverse
event so they favored the more effective and orally administered drug even if the
drug had adverse events more frequently. But patients and patients’ family mem-
bers showed reluctant attitudes about adverse events.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common cancers world-
wide. major treatment advances, however, have changed the assumptions about
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